Latest Information Update: 21 Dec 2015
At a glance
- Originator Xellia Pharmaceuticals
- Class Antibacterials
- Mechanism of Action Cell membrane modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 21 Dec 2015 Clinical trials in Cystic fibrosis-associated respiratory tract infections in Norway (Parenteral)